Evidence reviewed: 8 November 2026. Depression is more than an occasional sad day. Major depressive disorder (MDD) involves a sustained pattern of depressed mood and/or loss of interest, accompanied by other symptoms that interfere with health and daily functioning. There are effective options, including cognitive behavioral therapy (CBT), behavioral activation, other evidence-based psychotherapies and appropriately selected antidepressants. Treatment should be matched to severity, personal preference and safety. The NICE NG222 guideline, reviewed in January 2026, recommends different initial approaches for less severe versus more severe depression and emphasizes monitoring for suicidal thoughts and antidepressant withdrawal [1–3].
Recognizing depression symptoms
Major depression often includes low mood or markedly reduced pleasure in activities, together with several of the following:
- Persistently low energy or fatigue that interferes with usual tasks.
- Sleep changes, including difficulty falling or staying asleep, early awakening or sleeping much more than usual.
- Appetite or weight changes not explained by a planned diet or another illness.
- Difficulty concentrating, remembering details or making decisions.
- Feelings of guilt, worthlessness or hopelessness.
- Psychomotor slowing or agitation noticed by others.
- Withdrawal from relationships, work or study.
- Thoughts of death, self-harm or suicide, which require prompt and sensitive assessment [2,3].
Not everyone expresses sadness. Some people chiefly report loss of pleasure, irritability, unexplained physical symptoms or a feeling of emotional numbness. Cultural context, disability, age and other conditions influence how depression is described. Symptoms alone do not identify the cause or establish a diagnosis.
When does depression become a clinical disorder?
Under common diagnostic criteria, a major depressive episode involves at least five characteristic symptoms over the same two-week period, including either low mood or loss of interest or pleasure, with significant distress or impairment. A clinician also evaluates medical illness, medication or substance effects, bereavement context and a history of mania or hypomania [2,3].
Bipolar depression should not be automatically treated as unipolar depression. If there have been distinct periods of markedly increased energy, decreased need for sleep, grandiosity or risky behavior, assessment for bipolar disorder is necessary before deciding on antidepressants. See our bipolar disorder treatment guide [3,4].
Major depression versus other depressive conditions
| Condition or specifier | Important features | Management implication |
|---|---|---|
| Major depressive disorder | One or more qualifying major depressive episodes without a history of mania or hypomania. | Severity and individual preferences guide treatment. |
| Persistent depressive disorder | Chronic depressive symptoms, generally persisting at least two years in adults. | Requires long-term assessment and a sustained treatment plan. |
| Depression with psychotic features | Depression accompanied by delusions or hallucinations. | Needs specialist evaluation, often urgent, and tailored medicine or ECT. |
| Perinatal depression | Depressive illness during pregnancy or after birth. | Consider pregnancy, breastfeeding and infant-care safety. |
| Seasonal pattern | Depressive episodes recur at characteristic times of year. | Evaluate pattern and appropriate treatment; seasonal change alone is not diagnosis. |
| Adjustment-related or grief-related distress | Response to stress or loss that may or may not include a full depressive disorder. | Distinguish normal distress, other diagnoses and clinical depression without minimizing suffering. |
Why depression develops
Depression emerges from interactions among genetic vulnerability, psychosocial stressors, cognitive processes, sleep and circadian disturbances, physical illnesses and brain-network signaling. Serotonin, norepinephrine, dopamine, glutamate and inflammatory pathways have all been studied. It is inaccurate to claim that every depression episode is caused by a proven single “chemical imbalance” of serotonin [2,3].
Stress, violence, poverty, isolation and chronic illness can contribute, while some people experience depression without any obvious external trigger. The condition is not a personal failure, nor can it always be resolved by exercise, positive thinking or supplements alone.
Screening and diagnosis
Clinicians may use the Patient Health Questionnaire-2 (PHQ-2) or PHQ-9 to identify symptoms and follow improvement. A positive score is not a diagnosis on its own. Assessment includes episode duration, functioning, previous treatment, suicide risk, potential bipolar symptoms and medical or medication factors [1,2].
Testing for anemia, thyroid disease, sleep apnea, nutritional deficiencies or other physical causes is guided by findings rather than ordered as a universal battery. A person with unexplained fatigue and low mood deserves assessment of both possible depression and relevant medical conditions.
How severity changes treatment choice
NICE divides a new episode into less severe depression (including subthreshold and mild presentations) versus more severe depression, with preferences and impairment guiding care. For less severe depression, NICE recommends discussing treatments and considering the least intrusive appropriate option first, often guided self-help, behavioral activation or CBT. Antidepressants should not routinely be offered as first-line treatment for less severe depression, unless that is the person’s informed preference [1].
For more severe depression, reasonable initial choices can include individual CBT combined with an antidepressant, or other supported psychological or pharmacological approaches. The patient should participate in decisions with a clear explanation of benefits, burdens, safety and access [1].
Psychological therapies with evidence
| Treatment | How it may help | Practical considerations |
|---|---|---|
| Cognitive behavioral therapy (CBT) | Works with unhelpful thinking patterns, avoidance and behavior contributing to low mood. | Structured sessions with practice tasks; may be individual, group or suitable remote delivery. |
| Behavioral activation | Gradually increases meaningful and rewarding activity and reduces avoidance. | Useful when withdrawal and loss of routine maintain depression. |
| Interpersonal psychotherapy (IPT) | Addresses relationship changes, grief, conflicts and role transitions. | May be valuable when interpersonal stress is important. |
| Problem-solving therapy | Supports practical coping with identifiable life challenges. | Can be offered in selected clinical contexts. |
| Mindfulness-based cognitive therapy (MBCT) | Builds skills for recognizing thought patterns and preventing relapse. | Particularly used for relapse prevention in eligible patients. |
Professional therapy is different from being told simply to think positively. Social support, sleep care and exercise are useful complements, but more severe depression often requires structured clinical treatment [1,2].
Antidepressant medicines: main classes
Most antidepressants modify monoamine signaling or other brain pathways. SSRIs are often preferred initially because of a relatively favorable safety and tolerability profile, but drug selection is individualized.
| Class | Examples | Important cautions |
|---|---|---|
| SSRIs | Sertraline, escitalopram, fluoxetine | Nausea, sexual effects, sleep changes, hyponatremia, bleeding interactions and discontinuation concerns. |
| SNRIs | Venlafaxine, duloxetine | Possible blood-pressure effects, sweating, GI effects and important withdrawal symptoms. |
| Other antidepressants | Mirtazapine, bupropion, vortioxetine | Different effects on appetite, sleep, seizure threshold or drug interactions. |
| Tricyclic antidepressants | Amitriptyline, nortriptyline, others | Anticholinergic and cardiac effects; greater toxicity in overdose. |
| MAO inhibitors | Specialist-selected agents | Significant drug–food interactions and potentially dangerous serotonergic interactions. |
Antidepressants are not interchangeable. Prior benefit, risk of mania, pregnancy, heart disease, other prescriptions, cost and individual adverse effects must inform selection [1].
How quickly do antidepressants work?
Some symptoms begin to improve within one to two weeks, but overall response commonly develops over two to four weeks or longer. NICE recommends reviewing the patient within two to four weeks after starting treatment, checking adherence, side effects, clinical change and suicidal thinking [1].
For people aged 18–25 or those at increased suicide risk, NICE recommends an earlier review, about one week after starting or increasing an antidepressant, followed by further monitoring as required [1]. Do not judge failure from a single day or increase the dose without advice.
Antidepressant safety and withdrawal
Common adverse effects include GI discomfort, insomnia or sleepiness, headache, sweating and sexual dysfunction. More significant risks may include serotonin syndrome, hyponatremia, interactions with anticoagulants, increased bleeding, QT-related effects in selected agents and manic switching in susceptible patients. Young people need careful attention to new or worsening suicidal thoughts during initiation or dose changes [1].
Abrupt discontinuation can lead to dizziness, nausea, electric-shock sensations, agitation, insomnia and other withdrawal symptoms; these can sometimes be prolonged or mistaken for relapse. NICE advises gradual, individualized dose reduction, potentially using smaller steps as the dose becomes lower [1]. Never stop an effective prescribed antidepressant without discussing a safe plan.
How long should treatment continue after improvement?
For many people who respond to antidepressants, NICE recommends continuing medication for at least six months after remission, with regular review of benefits and harms [1]. A longer maintenance plan may be helpful after recurrent episodes, persistent residual symptoms, severe past episodes or high relapse risk. Psychological relapse-prevention approaches may also be appropriate.
There is no universal rule that everyone must take antidepressants for life or stop them exactly six months after feeling better. The plan should include personal preferences, side effects, earlier relapse history and safe tapering.
When depression does not improve with initial treatment
Before calling depression treatment resistant, reassess diagnosis, possible bipolar disorder, adherence, adequate medicine dose and duration, psychotherapy quality, substance use, sleep disorders and comorbid illness. NICE recommends shared decisions about adjusting or changing treatment rather than immediately combining many drugs [1].
Options may include switching to another antidepressant, adding structured psychotherapy, combining psychotherapy and medication, or carefully supervised augmentation in specialist care. Some augmentation strategies have significant metabolic, neurological or drug-interaction risks, so specialist assessment matters.
Esketamine, ECT and other specialist treatments
Intranasal esketamine (Spravato) is an NMDA receptor antagonist approved in the United States for treatment-resistant depression in adults, either as monotherapy or with an oral antidepressant under January 2025 FDA labeling. It is administered in a monitored healthcare setting due to risks including sedation, dissociation, respiratory depression and misuse, with specific REMS controls [4].
Esketamine is not proven to prevent suicide and does not eliminate the need for hospitalization in a dangerous acute crisis. It is not a general wellness spray or a substitute for assessing bipolar disorder. Availability and coverage vary [4].
Electroconvulsive therapy (ECT) is an evidence-based specialist treatment for severe depression, particularly when rapid improvement is essential, depression includes psychosis, or other treatments have failed. It is performed with anesthesia and appropriate monitoring; memory and other adverse effects must be discussed [1].
Repetitive transcranial magnetic stimulation (rTMS) may be considered in selected patients with inadequate response; clinical availability and protocols vary. No experimental intervention is universally appropriate.
Depression with psychotic symptoms
Severe depression accompanied by hallucinations, delusions or major inability to function requires prompt specialist evaluation. NICE advises treatment under specialist care and consideration of antidepressant plus antipsychotic treatment or ECT in suitable circumstances. Unsupervised ordinary antidepressant monotherapy may be inadequate and unsafe in severe psychotic illness [1].
Depression during pregnancy or postpartum
Pregnancy and breastfeeding require an individualized discussion of untreated illness risks, medication-specific effects, psychotherapy, infant health and personal preferences. Patients should not stop antidepressants abruptly solely because of a positive pregnancy test. See the related postpartum depression and breastfeeding guide for perinatal care considerations.
What can help alongside treatment?
Regular physical activity, adequate sleep, balanced nutrition, social connection, limiting alcohol and support with practical stressors can improve overall recovery. The effect of lifestyle changes varies and cannot reliably replace necessary treatment for moderate-to-severe depression. High-dose supplements, “serotonin detoxes” and unregulated herbal products should not be promoted as proven cures; interactions and toxicity can occur.
When should urgent help be sought?
Suicidal thoughts with intent, an active plan, psychosis, inability to remain safe, severe self-neglect or rapidly escalating agitation require urgent assessment. Contact local emergency services or a crisis team for imminent danger. A person who expresses suicidal thoughts should be heard sensitively and offered help, not dismissed or left unsupported.
Frequently asked questions
Does depression always involve feeling sad?
No. Loss of pleasure, withdrawal, physical symptoms or emotional numbness can be prominent [2].
Can a PHQ-9 score diagnose depression by itself?
No. It is a screening and monitoring tool; clinical evaluation is necessary.
Should everyone with mild depression start an antidepressant?
No. NICE advises against routinely offering antidepressants first-line for less severe depression unless it is the person’s informed preference [1].
How long should an antidepressant be continued?
Often for at least six months after remission, with a longer plan for some patients [1].
Is esketamine available for all depression cases?
No. It is a specialist, monitored option for specific indications and is not a universal first-line treatment [4].
Can depression be part of bipolar disorder?
Yes. Previous mania or hypomania changes treatment choice, particularly antidepressant safety.
Key takeaways
Depression treatment should match severity and individual needs. Psychological treatment is central, particularly in less severe depression, while SSRIs and other medicines are useful in appropriately selected patients. Screen for bipolar disorder, monitor suicide risk, and plan antidepressant continuation and withdrawal carefully.
References
- National Institute for Health and Care Excellence. Depression in adults: treatment and management (NG222). 2022; surveillance reviewed 30 Jan 2026.
- National Institute of Mental Health. Depression. NIH; accessed 8 Nov 2026.
- World Health Organization. Depressive disorder (depression): fact sheet. Accessed 8 Nov 2026.
- US Food and Drug Administration. Spravato (esketamine) prescribing information. Updated Jan 2025.
Medical disclaimer: Educational information only. Depression needs individual assessment and treatment planning. Do not self-prescribe, combine or suddenly stop antidepressants. Suicidal intent, severe psychosis or an inability to remain safe requires urgent professional care or emergency services.
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.